ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS

Clinical trials for ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS explained in plain language.

Never miss a new study

Get alerted when new ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS trials appear

Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug trial aims to tame dangerous autoimmune flares

Disease control Ongoing

This study is testing whether adding an investigational drug called iptacopan to standard treatment helps people with active ANCA-associated vasculitis. The goal is to achieve and maintain remission—a state with no disease activity—for longer periods while reducing the need for s…

Matched conditions: ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS

Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS

Get alerted when new ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS trials appear

New drug trial aims to tame dangerous autoimmune flares